Pharmaceuticals, Biotechnology and Life Sciences
Shire’s partner in Japan, Shionogi & Co has received the approval of the Japanese Ministry of Health, Labor and Welfare to manufacture and market Intuniv, a new, once-daily non-stimulant indicated for the treatment of attention deficit hyperactivity disorder (ADHD), a common psychiatric disorder in children and adolescents.
GlaxoSmithKline’s new CEO Emma Walmsley, who takes over on April 1, has won a short-term reprieve from the threat of generic Advair with a delay in U.S. approval for Mylan’s copy of the blockbuster lung inhaler.
Probiodrug AG, a Germany based biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer`s disease (AD), has announced its financial results for the twelve-month period ending 31 December 2016.
Oncodesign, a biotechnology company serving the pharmaceutical industry in the discovery of new therapeutic molecules to fight cancer and other serious illnesses with no known effective treatment, has reported its full-year 2016 results.
Amryt, the pharmaceutical company focused on treatments for rare and orphan diseases, has reported its final results for the year ended 31 December 2016.
Faron Pharmaceuticals, the clinical stage biopharmaceutical company, has reported full year audited results for the year ended 31 December 2016.
Allergy Therapeutics, the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announces its unaudited interim results for the six months ended 31 December 2016.
Alliance Pharma, the specialty pharmaceutical company, has announced results for the year ended 31 December 2016.
The Executive Board of Stada Arzneimittel AG has published the final figures for financial year 2016 which are, due to the revaluation of a transaction, diferent from the preliminary figures which the company had already published on March 1, 2017.
European Medicines Agency (EMA) has granted orphan designation to AstraZeneca’s and MedImmune’s inebilizumab (formerly MEDI-551) for the treatment of neuromyelitis optica spectrum disorder (NMOSD).